Pulmonary Embolism: Evidence Based Algorithm for Submassive and Massive PE Kenneth Rosenfield, MD, MHCDS, MSCAI Massachusetts General HospitalFaculty Disclosures Kenneth Rosenfield, MD, MHCDS, FACC, FAHA, MSCAI: consultant — Abbott Vascular, Access Vascular, BTG, Cardinal Health, SurModics, Cruzar Systems, Capture Vascular, Contego, Endospan, InspireMD, Magneto, Micell, Silk Road, Surmodics, Valcare, Volcano/Philips, Univ. of Maryland; Grant/ Research Support - Inari Medical, NIH; Major Stock Shareholder - Access Vascular, Contego, Embolitech, EXIMO, JanaCare Inc, MD Insider, Micelle, PQ Bypass Inc., Primacea; Other Financial or Material Support - Board Member: VIVA Physicians, a not-for-profit 501c3 organization dedicated to advancing the field of vascular medicine and intervention through education and research (www.vivapvd.com) Brand names are included in this presentation for participant clarification purposes only. ‘No product promotion should be inferred.Acute PE in the individual patient... Major conundrums facing the practitioner * Recognizing the presence of PE (“great masquerader”) * Calculating the relative risk to that patient is it“massive”, “submassive”, “low-risk”? * Determining optimal therapy * Choosing amongst a multitude of options for treatment, with very little evidence base/comparative effectiveness data to support one specific therapy over another WHAT IS THE RIGHT ALGORITHM TO FOLLOW?